Table A2.
Study by Treatment Agent | No. of Patients | Outcome Measure |
||
---|---|---|---|---|
Response Rate (%) | MTP (weeks) | 6-Month PFS (%) | ||
Gefitinib | ||||
Rich22 | 53 | NA | 8.1 | 13 |
Lieberman* | 38 | 13 | 8 | 9 |
Erlotinib | ||||
Vogelbaum11 | 31 | 6 | NS | 26 |
Raizer† | 31 | 0 | 12 | 0 |
Cloughesy‡ | 48 | 8 | NS | 17 |
Abbreviations: EGFR, epidermal growth factor receptor; MTP, median time to progression; PFS, progression-free survival; NA, not applicable; NS, not stated.
Lieberman FS, Cloughesy T, Malkin MG: J Clin Oncol 22:105, 2003 (abstr 421).
Raizer JJ, Abrey LE, Wen P, et al: J Clin Oncol 40:107, 2004 (abstr 1502).
Cloughesy T, Yung A, Vrendenberg J, et al: J Clin Oncol 41:115s, 2005 (abstr 1507).